Literature DB >> 26457955

Association of Deep Gray Matter Damage With Cortical and Spinal Cord Degeneration in Primary Progressive Multiple Sclerosis.

Serena Ruggieri1, Maria Petracca2, Aaron Miller3, Stephen Krieger3, Rezwan Ghassemi4, Yadira Bencosme3, Claire Riley5, Jonathan Howard6, Fred Lublin3, Matilde Inglese7.   

Abstract

IMPORTANCE: The investigation of cortical gray matter (GM), deep GM nuclei, and spinal cord damage in patients with primary progressive multiple sclerosis (PP-MS) provides insights into the neurodegenerative process responsible for clinical progression of MS.
OBJECTIVE: To investigate the association of magnetic resonance imaging measures of cortical, deep GM, and spinal cord damage and their effect on clinical disability. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional analysis of 26 patients with PP-MS (mean age, 50.9 years; range, 31-65 years; including 14 women) and 20 healthy control participants (mean age, 51.1 years; range, 34-63 years; including 11 women) enrolled at a single US institution. Clinical disability was measured with the Expanded Disability Status Scale, 9-Hole Peg Test, and 25-Foot Walking Test. We collected data from January 1, 2012, through December 31, 2013. Data analysis was performed from January 21 to April 10, 2015. MAIN OUTCOMES AND MEASURES: Cortical lesion burden, brain and deep GM volumes, spinal cord area and volume, and scores on the Expanded Disability Status Scale (score range, 0 to 10; higher scores indicate greater disability), 9-Hole Peg Test (measured in seconds; longer performance time indicates greater disability), and 25-Foot Walking Test (test covers 7.5 m; measured in seconds; longer performance time indicates greater disability).
RESULTS: The 26 patients with PP-MS showed significantly smaller mean (SD) brain and spinal cord volumes than the 20 control group patients (normalized brain volume, 1377.81 [65.48] vs 1434.06 [53.67] cm3 [P = .003]; normalized white matter volume, 650.61 [46.38] vs 676.75 [37.02] cm3 [P = .045]; normalized gray matter volume, 727.20 [40.74] vs 757.31 [38.95] cm3 [P = .02]; normalized neocortical volume, 567.88 [85.55] vs 645.00 [42.84] cm3 [P = .001]; normalized spinal cord volume for C2-C5, 72.71 [7.89] vs 82.70 [7.83] mm3 [P < .001]; and normalized spinal cord volume for C2-C3, 64.86 [7.78] vs 72.26 [7.79] mm3 [P =.002]). The amount of damage in deep GM structures, especially with respect to the thalamus, was correlated with the number and volume of cortical lesions (mean [SD] thalamus volume, 8.89 [1.10] cm3; cortical lesion number, 12.6 [11.7]; cortical lesion volume, 0.65 [0.58] cm3; r = -0.52; P < .01). Thalamic atrophy also showed an association with cortical lesion count in the frontal cortex (mean [SD] thalamus volume, 8.89 [1.1] cm3; cortical lesion count in the frontal lobe, 5.0 [5.7]; r = -0.60; P < .01). No association was identified between magnetic resonance imaging measures of the brain and spinal cord damage. CONCLUSIONS AND RELEVANCE: In this study, the neurodegenerative process occurring in PP-MS appeared to spread across connected structures in the brain while proceeding independently in the spinal cord. These results support the relevance of anatomical connectivity for the propagation of MS damage in the PP phenotype.

Entities:  

Mesh:

Year:  2015        PMID: 26457955     DOI: 10.1001/jamaneurol.2015.1897

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  14 in total

1.  Single scan quantitative gradient recalled echo MRI for evaluation of tissue damage in lesions and normal appearing gray and white matter in multiple sclerosis.

Authors:  Biao Xiang; Jie Wen; Anne H Cross; Dmitriy A Yablonskiy
Journal:  J Magn Reson Imaging       Date:  2018-08-29       Impact factor: 4.813

2.  The Impact of Intracortical Lesions on Volumes of Subcortical Structures in Multiple Sclerosis.

Authors:  I Kalinin; G Makshakov; E Evdoshenko
Journal:  AJNR Am J Neuroradiol       Date:  2020-05-07       Impact factor: 3.825

3.  Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis.

Authors:  A Burgetova; P Dusek; M Vaneckova; D Horakova; C Langkammer; J Krasensky; L Sobisek; P Matras; M Masek; Z Seidl
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-27       Impact factor: 3.825

Review 4.  Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale.

Authors:  Dimitrios Karussis; Panayiota Petrou
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

5.  The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis.

Authors:  Sheena L Dupuy; Shahamat Tauhid; Shelley Hurwitz; Renxin Chu; Fawad Yousuf; Rohit Bakshi
Journal:  Neurol Ther       Date:  2016-10-15

Review 6.  The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis.

Authors:  Maria A Rocca; Giancarlo Comi; Massimo Filippi
Journal:  Front Neurol       Date:  2017-09-04       Impact factor: 4.003

Review 7.  Advances in spinal cord imaging in multiple sclerosis.

Authors:  Marcello Moccia; Serena Ruggieri; Antonio Ianniello; Ahmed Toosy; Carlo Pozzilli; Olga Ciccarelli
Journal:  Ther Adv Neurol Disord       Date:  2019-04-22       Impact factor: 6.570

Review 8.  Brain imaging of locomotion in neurological conditions.

Authors:  Gilles Allali; Helena M Blumen; Hervé Devanne; Elvira Pirondini; Arnaud Delval; Dimitri Van De Ville
Journal:  Neurophysiol Clin       Date:  2018-10-25       Impact factor: 3.734

9.  Phase-Sensitive Inversion-Recovery MRI Improves Longitudinal Cortical Lesion Detection in Progressive MS.

Authors:  Asaff Harel; Antonia Ceccarelli; Colleen Farrell; Michelle Fabian; Jonathan Howard; Claire Riley; Aaron Miller; Fred Lublin; Matilde Inglese
Journal:  PLoS One       Date:  2016-03-22       Impact factor: 3.240

10.  Progression of regional grey matter atrophy in multiple sclerosis.

Authors:  Arman Eshaghi; Razvan V Marinescu; Alexandra L Young; Nicholas C Firth; Ferran Prados; M Jorge Cardoso; Carmen Tur; Floriana De Angelis; Niamh Cawley; Wallace J Brownlee; Nicola De Stefano; M Laura Stromillo; Marco Battaglini; Serena Ruggieri; Claudio Gasperini; Massimo Filippi; Maria A Rocca; Alex Rovira; Jaume Sastre-Garriga; Jeroen J G Geurts; Hugo Vrenken; Viktor Wottschel; Cyra E Leurs; Bernard Uitdehaag; Lukas Pirpamer; Christian Enzinger; Sebastien Ourselin; Claudia A Gandini Wheeler-Kingshott; Declan Chard; Alan J Thompson; Frederik Barkhof; Daniel C Alexander; Olga Ciccarelli
Journal:  Brain       Date:  2018-06-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.